Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies neutrophil traps in people with systemic sclerosis and related diseases

Looks at immune web-like structures in blood from adults with systemic sclerosis.

Key facts

Who runs it
CHU de Reims
Where
Reims, FranceSee the site
Trial code
Registry title
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Status
Recruiting
People taking part
260 people, planned
Started
27 Nov 2023
Expected to end
27 Apr 2029
Type of study
Observational, 3 groups
Treatments tested
  • Blood sample
Record updated
17 June 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with systemic sclerosis, adults with another connective tissue disease, and healthy volunteers. Everyone gives a blood sample.

Age
18 years or older
Sex
All sexes can join
Disease stage
Group 1: systemic sclerosis (ACR-EULAR criteria). Group 2: another connective tissue disease (ACR criteria for that disease). Group 3: healthy volunteers.
Earlier treatment
Healthy volunteers must not have taken anti-inflammatory drugs or corticotherapy in the last 15 days.

Main reasons for not taking part

  • Under 18 years old
  • Protected by the law
  • Acute inflammatory or infectious illness in the last 15 days
  • Pregnant or breastfeeding women
  • Healthy volunteers: autoimmune or chronic inflammatory disease, cancer now or in the past, chronic metabolic disease

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • *For patients of group 1:
  • Patients with systemic sclerosis (ACR-EULAR Criteria)
  • Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
  • Patients consenting to participate to the study
  • Patients enrolled in the national healthcare insurance program; For patients of group 2:
  • Patients with other connective tissue disease (ACR specific-disease criteria)
  • Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
  • Patients consenting to participate to the study
  • Patients enrolled in the national healthcare insurance program; For patients of group 3 (healthy volunteers)
  • Patients eligible for blood donation (blood donation regulation criteria of January 11th 2022 decree)
  • Patients without medical history of autoimmune systemic or chronic inflammatory systemic disease,
  • Patients without current or past neoplasy disease,
  • Patients without chronic metabolic pathology
  • Patients without treatment by anti inflammatory or corticotherapy for the last 15 days,
  • Patients without infectious pathology or inflammatory acute for the last 15 days
  • Patients consenting to participate to the study

Who cannot take part

  • Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion
  • Patients/Healthy volunteers under 18 years old
  • Patients/Healthy volunteers protected by the law
  • Patients/Healthy volunteers not consenting to participate to the study after information
  • Pregnant or breastfeeding women

Where in France

  • CHU ReimsReims, FranceContact: Damien JOLLY, Pr.Taking people

About the trial

What the trial wants to find out

Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the dysregulation of both innate and adaptive immune systems and may involve Reactive Oxygen Species (ROS).

Read full original descriptionShow less

Neutrophils are potent producers of ROS and may play a role in endothelial cells and fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC pathogenesis remains to be determined. Recent studies discovered abnormal regulation of Neutrophil Extracellular Traps (NETs) in other auto-immune diseases such as Systemic Lupus Erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and granular molecules. They are released by activated neutrophils through a process called "NETosis". Nets were first described in 2004 as a novel host defense mechanism to trap and kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis of a variety of inflammatory and autoimmune diseases, including SLE.

The investigators recently highlighted this phenomenon in SSc, especially in patients with vascular complications and/or at a early stage of the disease. The investigators will now explore the factors implicated in this dysregulation of NETosis in SSc.

The 3 groups in the trial

  • Adult with SSc

    Treatment: Blood sample

  • Other connective tissue disease

    Adult with other connective tissue disease

    Treatment: Blood sample

  • Control

    Healthy adult volunteer

    Treatment: Blood sample

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Neutrophil Extracellular Traps in Systemic Sclerosis
Plain-language title
Studies neutrophil traps in people with systemic sclerosis and related diseasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 June 2024